Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMMX Immix Biopharma, Inc.

Pre-Mkt 08-12 05:52:20 EDT

11.49

+1.36

+13.43%

盘前11.43

-0.06-0.52%

05:44 EDT

High11.55	Low9.92	Vol1.82M
Open10.14	D1 Closing10.13	Amplitude16.05%
Mkt Cap817.97M	Tradable Cap634.75M	Total Shares71.19M
T/O19.69M	T/O Rate3.30%	Tradable Shares55.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":11.49,"timestamp":1786478400000,"preClose":10.13,"halted":0,"volume":1821326,"hourTrading":{"tag":"盘前","latestPrice":11.43,"preClose":11.49,"latestTime":"05:44 EDT","volume":10,"amount":114.3,"timestamp":1786527882428,"change":-0.06,"changeRate":-0.005222,"amplitude":0},"delay":0,"changeRate":0.1342546890424481,"floatShares":55243700,"shares":71190000,"eps":-0.88,"marketStatus":"Pre-Mkt","change":1.36,"latestTime":"08-12 05:52:20 EDT","open":10.14,"high":11.5458,"low":9.92,"amount":19685672.756854,"amplitude":0.160494,"askPrice":11.48,"askSize":575,"bidPrice":10.67,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-0.88,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786541400000},"marketStatusCode":1,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":11.49,"preHourTrading":{"tag":"盘前","latestPrice":11.43,"preClose":11.49,"latestTime":"05:44 EDT","volume":10,"amount":114.3,"timestamp":1786527882428,"change":-0.06,"changeRate":-0.005222,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":11.49,"preClose":11.49,"latestTime":"19:34 EDT","volume":20295,"amount":232680.0477,"timestamp":1786491243244,"change":0,"changeRate":0,"amplitude":0.024883},"volumeRatio":1.1964351169145986,"impliedVol":1.4775,"impliedVolPercentile":0.76},"requestUrl":"/m/hq/s/IMMX/wiki","defaultTab":"wiki","newsList":[{"id":"2658914539","title":"Immix Biopharma Price Target Cut to $19.00/Share from $20.00 by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2658914539","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658914539?lang=en_us&edition=fundamental","pubTime":"2026-08-12 00:06","pubTimestamp":1786464360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658961829","title":"Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658961829","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658961829?lang=en_us&edition=fundamental","pubTime":"2026-08-11 17:31","pubTimestamp":1786440671,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) has an average rating of buy and mean price target of $20.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658568459","title":"Immix Biopharma Publishes Corporate Presentation on NXC-201 BCMA CAR-T in Relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2658568459","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658568459?lang=en_us&edition=fundamental","pubTime":"2026-08-11 03:31","pubTimestamp":1786390303,"startTime":"0","endTime":"0","summary":"Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosisImmix highlighted NXC-201, a BCMA-targeted CAR-T, as its lead program for relapsed or refrac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL83X1my:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936420","title":"Immix Biopharma is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936420","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936420?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:19","pubTimestamp":1786364340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938304","title":"Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938304","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938304?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359631,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immix Biopharma (IMMX), Ardelyx (ARDX) and Structure...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immix-biopharma-immx-ardelyx-ardx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immix-biopharma-immx-ardelyx-ardx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMMX","ARDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658198768","title":"Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $25 from $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2658198768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658198768?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:17","pubTimestamp":1786357063,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nAZN4TCYZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657621350","title":"Immix Biopharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657621350","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657621350?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:46","pubTimestamp":1786139196,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings SummaryImmix Biopharma, Inc.IMMX.OQreported a quarterly adjusted loss of 18 cents per share for the quarter ended June 30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657162990","title":"Immix Biopharma Q2 FY26 Net Loss Widens to USD 11.56 Million; G&A Expense More than Doubled to USD 7.12 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657162990","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657162990?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:06","pubTimestamp":1786136780,"startTime":"0","endTime":"0","summary":"Immix Biopharma Q2 FY26 net loss widens to USD 11.56 million; G&A expense more than doubled to USD 7.12 millionImmix Biopharma posted a net loss of USD 11.56 million for the quarter ended June 30, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL6kgjbr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657424562","title":"Immix Biopharma, Inc. Expected to Post a Loss of 18 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657424562","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657424562?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:55","pubTimestamp":1785876908,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. <IMMX.OQ> expected to post a loss of18cents a share - Earnings PreviewImmix Biopharma, Inc.IMMX.OQIMMX.Ois expected to  report resultson August 6 (estimated) for the period endin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N44132U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656559030","title":"Immix Biopharma to Attend Morgan Stanley Global Healthcare Conference, Host Investor Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559030","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559030?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:15","pubTimestamp":1785849335,"startTime":"0","endTime":"0","summary":"Immix Biopharma to attend Morgan Stanley Global Healthcare Conference, host investor meetingsImmix Biopharma will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL60MW0y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IAI","LU1162221912.USD","LU0225283273.USD","LU1732799900.SGD","SG9999014021.USD","LU0158827948.USD","BK4534","IE00B3S45H60.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU1244550221.USD","BK4581","LU0528227936.USD","LU1720051108.HKD","LU0098860793.USD","LU1791710582.SGD","LU2089284900.SGD","LU0557290698.USD","LU1668664300.SGD","LU2023251221.USD","LU2210150020.SGD","BK4504","LU0314104364.USD","LU0390134368.USD","SG9999014005.SGD","LU1988902786.USD","LU0158827781.USD","LU2210149790.SGD","LU0234570918.USD","IE00BN0W2T93.GBP","LU0795875086.SGD","BCDF","BK4127","LU1244550577.SGD","BK4516","IMMX","IE00BN0W2W23.USD","LU1791710400.SGD","LU2028103732.USD","LU0912757837.SGD","NDAQ","KBWB","IE00BKPKM429.USD","LU0882574139.USD","BK4139","LU0320765646.SGD","LU1074936037.SGD","LU0210528500.USD","LU1064131342.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653752161","title":"Immix Biopharma Initiated at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2653752161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653752161?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:27","pubTimestamp":1784719620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings(END) Dow Jones NewswiresJuly 22, 2026 07:27 ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653752931","title":"Needham Initiates Immix Biopharma at Buy With $21 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2653752931","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653752931?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:19","pubTimestamp":1784719172,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) has an average rating of buy and mean price target of $19.94, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653275453","title":"Immix Biopharma Inc : Needham Initiates Coverage with Buy Rating; Target Price $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2653275453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653275453?lang=en_us&edition=fundamental","pubTime":"2026-07-22 18:58","pubTimestamp":1784717902,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nFWN43O0QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652294716","title":"Immix Biopharma Terminates Richard Graydon Employment","url":"https://stock-news.laohu8.com/highlight/detail?id=2652294716","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652294716?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:06","pubTimestamp":1784542013,"startTime":"0","endTime":"0","summary":"Immix Biopharma terminates Richard Graydon employmentImmix Biopharma terminated Richard Graydon, effective July 17, 2026.Departure was described as unrelated to his activities at the company.Managemen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL5w6tqH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652795294","title":"Immix Biopharma - Richard Graydon Terminated from Immix Biopharma as of July 17, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2652795294","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652795294?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:06","pubTimestamp":1784541967,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nFWN43M04G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648806662","title":"Immix Biopharma Posts Corporate Presentation Highlighting Nxc-201 CAR-T in Relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2648806662","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648806662?lang=en_us&edition=fundamental","pubTime":"2026-07-03 23:50","pubTimestamp":1783093839,"startTime":"0","endTime":"0","summary":"Immix Biopharma posts corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosisImmix Biopharma highlighted NXC-201 BCMA-targeted CAR-T as a lead program for relapsed or r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260703:nNDLcdPF5Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644089202","title":"Immix Biopharma Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $27","url":"https://stock-news.laohu8.com/highlight/detail?id=2644089202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644089202?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:51","pubTimestamp":1781790680,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644880650","title":"BofA Initiates Immix Biopharma at Buy With $27 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2644880650","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644880650?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:55","pubTimestamp":1781783717,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) has an average rating of buy and mean price target of $19.79, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644872525","title":"Immix Biopharma Initiated at Outperform by LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2644872525","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644872525?lang=en_us&edition=fundamental","pubTime":"2026-06-18 02:48","pubTimestamp":1781722080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 14:48 ET (18:48 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644728162","title":"Immix Biopharma publishes corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644728162","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644728162?lang=en_us&edition=fundamental","pubTime":"2026-06-18 01:09","pubTimestamp":1781716143,"startTime":"0","endTime":"0","summary":"Immix outlined its NXC-201 BCMA-targeted CAR-T program for relapsed or refractory AL amyloidosis, highlighting a lack of FDA-approved therapies in this setting.Company materials cited a 95% complete response rate for NXC-201 in NEXICART-2, versus 0-10% for current investigator’s-choice regimens.Regulatory positioning highlighted FDA Breakthrough Therapy Designation in January 2026, RMAT in February 2025, Orphan Drug Designation in September 2023.Development timeline showed NEXICART-2 enrollment completion at 45 patients in March 2026, with the next update slated for late September 2026.Planned BLA submission targeted 1H 2027, with a commercial launch plan tied to approval in 1H 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL5VKvJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":0.2315},{"period":"1month","weight":0.0342},{"period":"3month","weight":0.0953},{"period":"6month","weight":0.5464},{"period":"1year","weight":3.9526},{"period":"ytd","weight":1.1969}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0207},{"period":"3month","weight":0.0381},{"period":"6month","weight":0.1311},{"period":"1year","weight":0.2117},{"period":"ytd","weight":0.13}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035123},{"month":2,"riseRate":0.2,"avgChangeRate":-0.05746},{"month":3,"riseRate":0.2,"avgChangeRate":-0.065433},{"month":4,"riseRate":0.4,"avgChangeRate":-0.025442},{"month":5,"riseRate":0.6,"avgChangeRate":0.091547},{"month":6,"riseRate":0.6,"avgChangeRate":0.103039},{"month":7,"riseRate":0.4,"avgChangeRate":-0.025858},{"month":8,"riseRate":0.4,"avgChangeRate":-0.007532},{"month":9,"riseRate":0.25,"avgChangeRate":0.017421},{"month":10,"riseRate":0.75,"avgChangeRate":0.171445},{"month":11,"riseRate":1,"avgChangeRate":0.264693},{"month":12,"riseRate":1,"avgChangeRate":0.380003}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc.","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immix Biopharma, Inc.,IMMX,Immix Biopharma, Inc.股票,Immix Biopharma, Inc.股票老虎,Immix Biopharma, Inc.股票老虎国际,Immix Biopharma, Inc.行情,Immix Biopharma, Inc.股票行情,Immix Biopharma, Inc.股价,Immix Biopharma, Inc.股市,Immix Biopharma, Inc.股票价格,Immix Biopharma, Inc.股票交易,Immix Biopharma, Inc.股票购买,Immix Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}